Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115

Boiko, S. S.; Колыванов, Г. Б.; Zherdev, V. P.; Gudasheva, T. A.; Kir’yanova, E. P.; Середенин, С. Б.

doi:10.1007/s10517-007-0319-0

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GB-115 (N-phenylhexanoyl-glycyl-L-tryptophan amide) was synthesized at the Department of Chemistry (V. V. Zakusov Institute of Pharmacology). Pharmacological study showed that the dipeptide GB-115 is present in blood plasma after peroral administration and injection [3]. Taking into account the results of previous experiments, GB-115 was administered in doses of 0.1-10 mg/kg [6].…”

Section: Methodsmentioning

confidence: 99%

Immunocorrecting properties of GB-115 dipeptide

et al. 2008

Self Cite

View full text Add to dashboard Cite

We studied the effects of a new dipeptide with anxiolytic activity (GB-115, N-phenylhexanoyl-glycyl-L-tryptophan amide) on parameters of the immune in intact mice and in animals with secondary immunodeficiency caused by cyclophosphamide. GB-115 in doses of 0.1-10 mg/kg stimulated phagocytic activity of peritoneal macrophages and humoral immune response in intact mice. GB-115 exhibited immunocorrecting activity in animals with secondary immunodeficiency.

show abstract

Section: Methodsmentioning

confidence: 99%

Immunocorrecting properties of GB-115 dipeptide

et al. 2008

Self Cite

View full text Add to dashboard Cite

show abstract

“…These data are necessary for appropriate use of drugs: individual adjustment of the optimal therapeutic dose, treatment regimen, and permissible combination of drugs, detection of active metabolites, and prevention of adverse reactions. In this regard, experimental pharmacokinetic studies are an essential stage of preclinical trials of new drugs [1][2][3][4][5][6]9].…”

mentioning

confidence: 99%

Study of the Absolute Bioavailability of Citrocard, a New GABA Derivative

et al. 2013

View full text Add to dashboard Cite

The main pharmacokinetic parameters attest to short elimination half-life and mean retention time of a single citrocard molecule. The average rate of plasma concentration decrease of the compound determined small area under the pharmacokinetic curve. Steady-state distribution volume was low and only slightly surpassed the volume of extracellular body fluids in rat, which indicated moderate capacity of citrocard to distribution and accumulation in the tissues, which is seen from low systemic clearance (Cl) despite the quick elimination of the compound. Absolute bioavailability was 64%.

show abstract

Anxiolytic Activity of Dipeptide GB-115 after Oral Administration

et al. 2013

View full text Add to dashboard Cite

The anxiolytic effects of GB-115, a retroanalogue of cholecystokinin-4, administered orally to outbred and inbred animals with different level of emotionality, were studied in the open field test and elevated plus-maze test. The anxiolytic effect of talanax was observed in outbred mice (0.1-0.5 mg/kg) and in inbred BALB/c mice (0.1 and 5.0 mg/kg) in the open field test. GB-115 increased the time of entries into open arms in outbred rats (0.5-0.7 mg/kg) and in BALB/c mice (0.1 mg/kg). These data confirmed the dependence of GB-115 effect on the phenotype of emotional stress response and demonstrated a shift of anxiolytic doses of the preparation from 0.006-0.100 mg/kg in intraperitoneal administration to 0.1-5.0 mg/kg in oral treatment.

show abstract

Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115

Cited by 5 publications

References 3 publications

Immunocorrecting properties of GB-115 dipeptide

Immunocorrecting properties of GB-115 dipeptide

Study of the Absolute Bioavailability of Citrocard, a New GABA Derivative

Anxiolytic Activity of Dipeptide GB-115 after Oral Administration

Contact Info

Product

Resources

About